Tetrabuthylammonium

Tetrabuthylammonium

SCHEMBL6473273

CCCC[N+](CCCC)(CCCC)CCCC.c1ncc2nc[nH]c2n1

nearest known ligand 0.36

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC22A1 O15245 3/20 0.36
HRH3 Q9Y5N1 3/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
XDH P47989 1/20 0.33
PAK1 Q13153 1/20 0.33
SLC22A2 O15244 1/20 0.32
EPHX1 P07099 1/20 0.32
CDK1 P06493 2/20 0.31
CCNB1 P14635 2/20 0.31
CCNA2 P20248 1/20 0.31
CDK2 P24941 1/20 0.31
CCNA1 P78396 1/20 0.31
HRH4 Q9H3N8 2/20 0.31
LATS1 O95835 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Purine SCHEMBL3021752 0.80 KDM4A (0.36)
Purine SCHEMBL3157 0.80
Purine SCHEMBL2120547 0.80 KDM4A (0.38) XDH
Purine SCHEMBL9603027 0.78
Purine SCHEMBL6438162 0.78 KDM4A (0.37)
Purine SCHEMBL311318 0.78 KDM4A (0.37)
Tetrabuthylammonium SCHEMBL6473275 0.76 PAK1 (0.41) SLC22A1HRH3XDHPAK1CDK1
Purine SCHEMBL20520352 0.75 KDM4A (0.39)
Purine SCHEMBL1827535 0.75 KDM4A (0.35)
Purine SCHEMBL7787939 0.73 KDM4A (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1535923-A1 Synthesis of acyclic nucleoside derivatives Medivir Aktiebolag (SE) 2005-06-01 EP disclosed
EP-1131323-A1 SYNTHESIS OF ACYCLIC NUCLEOSIDE DERIVATIVES Medivir Aktiebolag (SE) 2001-09-12 EP disclosed
WO-2000008025-A1 SYNTHESIS OF ACYCLIC NUCLEOSIDE DERIVATIVES MEDIVIR AB (SE) 2000-02-17 WO disclosed